Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19
Effat Davoudi-Monfared, Hamid Rahmani, Hossein Khalili, et al.
Antimicrobial Agents and Chemotherapy (2020) Vol. 64, Iss. 9
Open Access | Times Cited: 287

Showing 26-50 of 287 citing articles:

Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence
Hui Lin, Sanda Cho, Veeraraghavan Meyyur Aravamudan, et al.
Infection (2021) Vol. 49, Iss. 3, pp. 401-410
Open Access | Times Cited: 87
Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics
Konstantin Chumakov, Michael S. Avidan, Christine Stabell Benn, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 21
Open Access | Times Cited: 86
Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Sophie Juul, Emil Eik Nielsen, Joshua Feinberg, et al.
PLoS Medicine (2020) Vol. 17, Iss. 9, pp. e1003293-e1003293
Open Access | Times Cited: 84
A genetic link between risk for Alzheimer's disease and severe COVID-19 outcomes via the OAS1 gene
Naciye Magusali, Andrew Graham, Thomas M. Piers, et al.
Brain (2021) Vol. 144, Iss. 12, pp. 3727-3741
Open Access | Times Cited: 83
COVID-19 virtual patient cohort suggests immune mechanisms driving disease outcomes
Adrianne L. Jenner, Rosemary A. Aogo, Sofia Alfonso, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 7, pp. e1009753-e1009753
Open Access | Times Cited: 79
Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome
Yaseen M. Arabi, Ayed Y. Asiri, Abdullah M. Assiri, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 17, pp. 1645-1656
Closed Access | Times Cited: 73
The role of type I interferon in the treatment of COVID‐19
Fatemeh Sodeifian, Mahsa Nikfarjam, Naghmeh Kian, et al.
Journal of Medical Virology (2021) Vol. 94, Iss. 1, pp. 63-81
Open Access | Times Cited: 73
Blood Interferon-α Levels and Severity, Outcomes, and Inflammatory Profiles in Hospitalized COVID-19 Patients
Marco Contoli, Alberto Papi, Luca Tomassetti, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 72
Potential role of interferons in treating COVID-19 patients
Mohadeseh Haji Abdolvahab, Shima Moradi‐Kalbolandi, Mohammad Zarei, et al.
International Immunopharmacology (2020) Vol. 90, pp. 107171-107171
Open Access | Times Cited: 71
Cellular Immune Response to COVID-19 and Potential Immune Modulators
Xi Zhou, Qing Ye
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 69
JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis
Lucas Walz, Avi J. Cohen, André Rebaza, et al.
BMC Infectious Diseases (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 66
SARS-CoV-2 Antiviral Therapy
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Clinical Microbiology Reviews (2021) Vol. 34, Iss. 4
Open Access | Times Cited: 57
Oral nano‐curcumin formulation efficacy in the management of mild to moderate outpatient COVID‐19: A randomized triple‐blind placebo‐controlled clinical trial
رضا احمدی, Soofia Salari, Mohammad Davood Sharifi, et al.
Food Science & Nutrition (2021) Vol. 9, Iss. 8, pp. 4068-4075
Open Access | Times Cited: 55
Trained Immunity: An Overview and the Impact on COVID-19
Justin M. Brueggeman, Juan Zhao, Madison Schank, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 46
Interferon induction, evasion, and paradoxical roles during SARS‐CoV‐2 infection*
Carolina Chiale, Trever T. Greene, Elina I. Zúñiga
Immunological Reviews (2022) Vol. 309, Iss. 1, pp. 12-24
Open Access | Times Cited: 46
Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions
Yujie Jiang, Tingmei Zhao, Xueyan Zhou, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 42
Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences
Reem Hoteit, Hadi M. Yassine
Vaccines (2022) Vol. 10, Iss. 6, pp. 919-919
Open Access | Times Cited: 38
Interfering with Interferons: A Critical Mechanism for Critical COVID-19 Pneumonia
Helen C. Su, Huie Jing, Yu Zhang, et al.
Annual Review of Immunology (2023) Vol. 41, Iss. 1, pp. 561-585
Open Access | Times Cited: 31
Antiviral Therapy of COVID-19
Georgii Gudima, И.А. Кофиади, I.P. Shilovskiy, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8867-8867
Open Access | Times Cited: 24
Combining Antivirals and Immunomodulators to Fight COVID-19
Vincent Feuillet, Bruno Canard, Alain Trautmann
Trends in Immunology (2020) Vol. 42, Iss. 1, pp. 31-44
Open Access | Times Cited: 58
Susceptibility to severe COVID-19
David B. Beck, Ivona Aksentijevich
Science (2020) Vol. 370, Iss. 6515, pp. 404-405
Closed Access | Times Cited: 50
Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection
Marcello Allegretti, Maria Candida Cesta, Mara Zippoli, et al.
Cell Death and Differentiation (2021) Vol. 29, Iss. 1, pp. 156-166
Open Access | Times Cited: 50
TLRs in COVID-19: How they drive immunopathology and the rationale for modulation
F. Linzee Mabrey, Eric D. Morrell, Mark M. Wurfel
Innate Immunity (2021) Vol. 27, Iss. 7-8, pp. 503-513
Open Access | Times Cited: 49
Current evidence for COVID-19 therapies: a systematic literature review
Tobias Welte, Lucy Ambrose, Gillian C. Sibbring, et al.
European Respiratory Review (2021) Vol. 30, Iss. 159, pp. 200384-200384
Open Access | Times Cited: 46
Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Sophie Juul, Emil Eik Nielsen, Joshua Feinberg, et al.
PLoS ONE (2021) Vol. 16, Iss. 3, pp. e0248132-e0248132
Open Access | Times Cited: 44

Scroll to top